NEW YORK (GenomeWeb News) – German firm Mosaiques Diagnostics and Therapeutics has inked a contract with the US Food and Drug Administration to collaborate on the discovery and validation of biomarkers for assessing drug toxicity.
Under the partnership, the FDA will provide information about drugs, expected toxicities, and animal studies. Mosaiques will contribute its proteome analysis expertise, particularly in sample preparation of urine and capillary electrophoresis coupled mass spectrometry.
"We are aiming to reduce or even prevent adverse effects of drugs by implementing our technology in preclinical testing," Mosaiques Founder and CSO Harald Mischak, said in a statement. "This agreement with the FDA underlines the potential of the protein pattern technology for modern medicine and appropriate treatment."
Further terms of the collaboration were not disclosed.